Related Resources

Tom Wilbur

Tom Wilbur is Deputy Vice President of Public Affairs at PhRMA where he leads the state public affairs team and Voters for Cures, PhRMA’s grassroots advocacy initiative. Prior to joining PhRMA in 2019, Tom served as a senior aide on Capitol Hill for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom holds an M.A. in strategic communications from Michigan State University and a B.A. in social science and history from Central Michigan University. He enjoys spending time with family and friends, volunteering, reading and golfing.

Author Twitter

Author LinkedIn

Voters continue to voice their concerns on government price controls

July 24, 2026

Voters voice concerns on government price controls

April 7, 2026

CMS needs to do better

November 4, 2024

New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election

October 30, 2024

Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?

October 18, 2024

Where voters stand ahead of the election

October 16, 2024

Key voter insights two months from Election Day

September 10, 2024

Key election year voter insights

June 6, 2024

ICYMI: Voter priorities this election season

April 18, 2024

Voter insights: Four things to know

March 7, 2024

One year to Election Day: Four voter priorities to watch

November 6, 2023

In their own words: Insured Americans support policy reforms that address access and affordability concerns

December 14, 2022

In their own words: Financial barriers exacerbate access challenges for insured Americans

December 8, 2022

In their own words: Insured Americans struggle to navigate complex coverage

October 26, 2022

Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients

July 12, 2022

5 public opinion polling trends to watch

April 22, 2022

Legislation threatens patent protections and future innovation

January 12, 2022

Three things to know about so-called Medicare negotiation polling

November 18, 2021

Recent polling misrepresents public support for Medicare “negotiation”

August 31, 2021

Myth vs. fact: Polling and Medicare “negotiation”

August 12, 2021

Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery

July 2, 2021

Four solutions Americans support to make health care more affordable

May 13, 2021

ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy

March 11, 2021

Key excerpts: PhRMA submits comments to keep the six protected classes protected

February 19, 2021

The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing

February 12, 2021

Action needed to preserve the six protected classes

February 3, 2021

Key facts: The final rebate rule will be a positive change for patients

January 19, 2021

End of year Part D reading List

December 18, 2020

Insights from the election: Meeting voters where they are on health care

December 15, 2020

Final rebate rule represents right way to change Medicare

December 1, 2020

Deep dive: The issues that drove the 2020 vote

November 13, 2020

New video: See how strong IP protections lead to stronger treatments for patients

November 9, 2020

Voters want to address the real drivers of health care costs for patients and the system

November 2, 2020

How does Medicare Part D impact you?

October 21, 2020

Open Enrollment: How to find a Medicare plan that meets your needs

October 14, 2020

Three reasons why repealing the Part D non-interference clause is a bad idea

October 1, 2020

Why the U.S. biopharmaceutical industry is leading the charge against COVID-19

September 30, 2020

National Medicare Education Week: The history of Medicare Part D

September 15, 2020

How Medicare Part D supports patients

September 1, 2020

Supporting access to vaccines for Part D beneficiaries

August 12, 2020

Medicare’s 55th anniversary: Celebrating the success of Part D

July 30, 2020

The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19

July 22, 2020

Three reasons why MedPAC’s latest Part D proposal would be bad for patients

July 14, 2020

The latest: What they are saying: Importance of intellectual property protections to combat COVID-19

July 2, 2020

The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19

June 5, 2020

What they are saying: Intellectual property protections are critical as we work to defeat COVID-19

May 4, 2020

New infographic: How we are fighting COVID-19

April 8, 2020

PhRMA submits comments on CMS’s Part D specialty tier proposal

April 7, 2020

IP Explained: Four key takeaways from new Bayh-Dole white paper

February 19, 2020

What you need to know about H.R. 3

December 12, 2019

Pelosi’s radical plan would leave patients with sickle cell disease behind

November 14, 2019

Pelosi’s radical plan would leave patients with rare pediatric diseases behind

November 7, 2019

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

November 4, 2019

What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation

October 31, 2019

Pelosi’s radical plan leaves lung cancer patients behind

October 23, 2019

Pelosi’s radical plan would leave Alzheimer’s patients behind

October 16, 2019

Pelosi’s radical plan would leave ALS patients behind

October 15, 2019

What they are saying: Broad opposition to Pelosi’s radical drug pricing plan

October 10, 2019

IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act

October 9, 2019

By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk

September 26, 2019

Four reasons why the radical Pelosi Plan is the wrong approach

September 24, 2019

IP Explained: Four things to know about the Bayh-Dole Act

September 13, 2019

IP Explained: Three forms of IP protections for medicines

August 27, 2019

Three reasons the Senate Finance package is the wrong approach for patients

August 26, 2019

Four Things You Should Know About AARP

August 14, 2019

IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle

August 6, 2019

IP Explained: Why IP protections are important for biologic medicines

July 18, 2019

IP Explained: What is Section 101 and why reforms are needed

June 26, 2019

How the rebate rule would help reduce patients’ out-of-pocket costs

June 3, 2019

What you need to know about the CBO rebate rule score

May 23, 2019

IP Explained: How Hatch-Waxman successfully balances affordability and innovation

May 22, 2019

IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry

May 2, 2019

IP Explained: What they are saying on the importance of strong intellectual property protections

April 24, 2019

IP Explained: Why patents are so critical to biopharmaceutical innovation

April 16, 2019

Bipartisan lawmakers urge Administration to rethink proposed changes to six protected classes policy

March 22, 2019

New report: Using march-in authority would jeopardize U.S. innovation

March 19, 2019

Changes to the six protected class policy are the wrong prescription for Medicare and HIV patients

March 15, 2019

Repealing Part D noninterference clause threatens access and choice for America’s seniors

March 5, 2019